MedTrace Logo

Pharmacoinvasive Therapy With Prourokinase

NCT01642667 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2012-07-27

No results posted yet for this study

Summary

The aim of this study is to elucidate the efficacy and safety of pharmacoinvasive therapy by using prourokinase (prouk), a unique fibrin-specific agent, in patients with ST-segment elevation myocardial infarction (STEMI)

Conditions

  • ST-segment Elevation Myocardial Infarction (STEMI)

Interventions

DRUG

Prourokinase

a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.

DRUG

Placebo

Sponsors & Collaborators

  • Suzhou Landing Pharmaceuticals

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-11-30
Completion
2010-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01642667 on ClinicalTrials.gov